semaglutide 0.6 mg (Ozempic/Wegovy) shows 3-year efficacy for blood sugar control and weight loss BodyPharm Semaglutide 6mg – My

Novo Nordisk announced that the FDA has approved Ozempic (semaglutide injection) to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to

This webinar with obesity medicine physician Jonathan Bonnet, MD, MPH, a GLP-1RA expert, will answer all your questions about the medications, how they work, their benefits, their side effects, and how they can be combined with lifestyle changes to optimize your weight loss and body composition.

Understanding contraindicationsfrom thyroid cancer history to pregnancyhelps determine if GLP-1 therapy is right for you

Jack Husney helps you choose the best colonoscopy prep based on comfort, safety, and results.

GLP-1 Receptor Agonists and Aspiration Risk: From Universal Holding to Risk-Based Perioperative Management Review Abstract Purpose The rapid adoption ofglucagon-like peptide-1 receptor agonists (GLP-1 RAs)anddual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonistshas transformed the management of type 2 diabetes mellitus and obesity